In the last trading session, 1.32 million shares of the Capricor Therapeutics Inc (NASDAQ:CAPR) were traded, and its beta was 4.60. Most recently the company’s share price was $16.00, and it changed around $2.33 or 17.04% from the last close, which brings the market valuation of the company to $727.51M. CAPR currently trades at a discount to its 52-week high of $23.40, offering almost -46.25% off that amount. The share price’s 52-week low was $3.52, which indicates that the current value has risen by an impressive 78.0% since then.
Capricor Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended CAPR as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Capricor Therapeutics Inc is expected to report earnings per share of -0.09 for the current quarter.
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
Instantly CAPR has showed a green trend with a performance of 17.04% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 16.07 on recent trading dayincreased the stock’s daily price by 0.44%. The company’s shares are currently up 15.94% year-to-date, but still up 1.27% over the last five days. On the other hand, Capricor Therapeutics Inc (NASDAQ:CAPR) is 6.38% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $15, which translates to bulls needing to decrease their stock price by -6.67% from its current value. Analyst projections state that CAPR is forecast to be at a low of $10 and a high of $21.5.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
The year-over-year growth rate is expected to be -16.70%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 9.87M in revenue for the current quarter. 3 analysts expect Capricor Therapeutics Inc to make 2.17M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 12.09M and 4.91M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -18.35%. Forecasts for the next quarter put sales growth at -55.84%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 30.59%.
Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders
VANGUARD GROUP INC, with 4.9401% or 1.55 million shares worth $7.39 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024. The former held 1.44 shares worth $22.45 million, making up 3.16% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 994.25 shares worth around $15.51 million, which represents about 2.19% of the total shares outstanding.
